Hypothesis

Rapamycin’s longevity effect is driven not only by mTORC1 inhibition but by a distinct nucleolar stress response that preserves ribosomal DNA (rDNA) integrity and attenuates the senescence‑associated secretory phenotype (SASP). This pathway is activated via FKBP12‑rapamycin binding to mTORC2, which reduces Akt‑mediated phosphorylation of FOXO transcription factors, allowing FOXO‑dependent up‑regulation of nucleophosmin (NPM1) and downstream repression of RNA polymerase I (POLI) transcription. Stabilized rDNA lowers nucleolar stress‑induced DNA damage signaling, thereby limiting chronic inflammation and tissue dysfunction. Because this mechanism does not rely on global translation suppression or metabolic stress signatures, it can operate even when caloric restriction fails, explaining rapamycin’s efficacy when initiated late in life.

Testable Predictions

1. rDNA stability – Old mice treated with rapamycin will show reduced rDNA copy‑number variation and lower γH2AX foci at nucleolar organizers compared with age‑matched controls; this effect will be absent in mice lacking NPM1 in hematopoietic or mesenchymal lineages.
2. SASP attenuation – Rapamycin treatment will decrease circulating IL‑6, TNF‑α, and MCP‑1 levels, and reduce SASP‑gene expression (e.g., Cxcl1, MMP3) in sorted senescent cells; NPM1 knockout will abolish these changes.
3. mTORC2 dependence – Mice with rapamycin‑resistant mTORC2 (Rictor^S1235A) will not exhibit the rDNA‑stabilizing or SASP‑suppressing effects of rapamycin, despite normal mTORC1 inhibition.
4. Additivity with CR – Combining rapamycin with caloric restriction will yield a greater lifespan extension than either intervention alone, because CR primarily reduces IGF‑1/insulin signaling while rapamycin targets the nucleolar stress axis.
5. Late‑life efficacy – Initiating rapamycin at 20 months will improve rDNA integrity and lower SASP markers, whereas caloric restriction started at the same age will not.

Experimental Approach

• Mouse cohorts: Wild‑type, NPM1‑conditional knockout, and Rictor^S1235A lines; both sexes; n≥30 per group for survival analysis.
• Interventions: Rapamycin encapsulation (14 ppm diet), 30 % caloric restriction, and combined treatment; start at 8 weeks (early) or 20 weeks (late).
• Readouts: Whole‑genome sequencing for rDNA copy‑number variation; immunofluorescence for nucleolar size, NPM1 localization, and γH2AX; RNA‑seq of FACS‑sorted p16^Ink4a^+ senescent cells; plasma cytokine multiplex; survival curves.
• Falsification: If rapamycin fails to improve rDNA stability or reduce SASP in wild‑type mice, or if NPM1 loss or mTORC2 resistance does not blunt these effects, the hypothesis is refuted.

Mechanistic Insight

The nucleolus functions as a stress sensor linking growth signaling to genome stability. By modulating mTORC2‑FOXO‑NPM1 signaling, rapamycin may reinforce a homeostatic state where ribosome biogenesis is tempered without the energetic deficit of famine. This preserves proteostasis by limiting the production of error‑prone ribosomal subunits while concurrently dampening inflammatory signaling that drives aging phenotypes. Unlike CR, which primarily reduces intracellular acetyl‑CoA and NAD^+ levels, the nucleolar route directly guards the genetic template for protein synthesis, offering a complementary explanation for rapamycin’s ability to act when metabolic interventions are ineffective.

By integrating transcriptomic, proteomic, and metabolomic layers—particularly measuring rDNA transcription rates, NPM1‑dependent POLI activity, and SASP metabolites—we can mathematically deconvolve the shared versus unique contributions of rapamycin and caloric restriction. Confirming that the nucleolar axis accounts for a significant fraction of rapamycin’s lifespan benefit would shift the paradigm from "impersonating scarcity" to "actively safeguarding the cell’s synthetic machinery."